Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Mouth spray could curb virus spread in the air

NCT ID NCT07041671

Disease control Sponsor: Lund University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether ColdZyme mouth spray can lower the amount of virus people breathe out when they have a cold or flu. Researchers will measure virus particles in exhaled air before and after using the spray. The goal is to see if the spray might help reduce airborne transmission of respiratory viruses.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ColdZyme mouth spray (a medical device that forms a protective barrier in the mouth and throat)
What this could lead to
If it works, this could show that a simple mouth spray helps reduce the spread of cold and flu viruses from infected people.
What could go wrong
This is an early study with only one dose, and it measures virus levels in breath, not actual infection rates. The spray may not significantly reduce transmission in real-world settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 200 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2025

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria for subject selection: * Male and female subjects above age 18 (inclusive). * Presence of self-reported sudden onset of at least one of the following symptoms of upper respiratory tract infection case definitions for ILI and ARI (as defined by ECDC (EU 2008, 2012, 2022): Cough, sore throat, shortness of breath, non-allergic rhinitis, fever or feverishness, malaise, headache, myalgia. * Otherwise of general good health, according to Investigator's judgement. * Willing and able to give written informed consent for participation in the investigation. Exclusion criteria for subject selection. * Known allergy or hypersensitivity to the components of ColdZyme. * Current use of immunosuppressive therapy within the last 4 weeks prior to Visit 1 and during the investigation. * Diagnosed chronic respiratory disease that could potentially impact the investigation results, according to Investigator's judgement. * Self-reported unhealed wounds/mucosal lesions in the mouth and/or throat. * Participation in another clinical study or investigation within 30 days prior to Visit 1. * Active smokers * The Investigator considers the subject unlikely to comply with investigational procedures, restrictions and requirements.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Upper respiratory tract infection are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

respiratory tract infectious disorder viral respiratory tract infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Urti - viral upper respiratory tract infection

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Lund University

    RECRUITING

    Lund, 22100, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.